Pfizer Inc. — FY2018 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2018. This is an annual filing, not a quarterly report; the supplied text does not provide standalone fourth-quarter results. Pfizer is a global biopharmaceutical company selling medicines, vaccines and consumer healthcare products in more than 125 countries.
Key financial and operating metrics
| Metric | FY2018 |
|---|---|
| Total revenue | Approximately $53.6 billion |
| Innovative Health revenue | Approximately $33.4 billion |
| Essential Health revenue | Approximately $20.2 billion |
| Research and development expense | Approximately $8 billion |
| Revenue from outside the U.S. | $28.3 billion, or 53% of total revenue |
| Products with more than $1 billion in direct product and/or alliance revenue | 10; together represented 51% of total revenue |
| Fourth-quarter share repurchases | 114.8 million shares under the announced plan, at an average $43.83 per share |
The supplied filing text does not provide clear values for net income, operating profit, cash flow, margins, debt, or cash and short-term investments. It refers readers to the incorporated 2018 Financial Report for full financial statements and discussion. Management stated that global economic conditions were not expected to materially affect liquidity or capital resources and cited operating cash flows, financial assets, capital-market access and credit facilities, but specific liquidity amounts are not included here.
Material changes and developments
- Pfizer agreed to combine its Consumer Healthcare business with GSK’s in a new joint venture. Pfizer was to contribute its business for a 32% equity interest, with GSK holding 68%. Closing was expected in the second half of 2019, subject to approvals and other conditions.
- Effective at the start of 2019, Pfizer reorganized its commercial operations into three businesses: Biopharmaceuticals Group, Upjohn and Consumer Healthcare. FY2018 segment reporting remains based on the former Innovative Health and Essential Health structure.
- Pfizer announced it would end internal neuroscience discovery and early development, while continuing development of tanezumab and potential treatments for rare neuromuscular disorders. Certain neuroscience assets were transferred to a new company formed with Bain Capital.
- The filing identifies upcoming or recent exclusivity pressure, including U.S. Lyrica exclusivity ending in June 2019 and generic Viagra entry in the U.S. in December 2017.
Outlook, commentary and principal risks
- The filing refers to 2019 financial guidance in the incorporated Financial Report; the supplied text does not provide the guidance figures.
- Management reported periodic shortages of select raw materials in 2018 but anticipated no significant operational impact in 2019. Separately, sterile-injectable supply constraints, technical issues and supplier quality concerns at legacy Hospira facilities remained a risk.
- The McPherson manufacturing facility was classified by the FDA as Official Action Indicated after a 2018 inspection. Pfizer said corrective actions were ongoing; FDA restrictions could delay approvals or export certificates for products made there. Meridian facilities also remained subject to corrective actions following an FDA warning letter.
- Major business risks include generic and biosimilar competition, patent challenges, pricing and reimbursement pressure, payer restrictions, regulatory and clinical-development uncertainty, foreign-exchange exposure, supply disruption, and reliance on key products. Ten products accounted for 51% of revenue, creating concentration risk.
- Three leading biopharmaceutical wholesalers represented approximately 37% of total revenue and 76% of U.S. revenue in 2018. The filing also cites changing U.S. and international drug-pricing policies as potential sources of pressure.
- Pfizer entered a five-year Corporate Integrity Agreement in May 2018 following resolution of a U.S. government investigation concerning independent copay-assistance organizations.
Important facts for investors to verify
- Review the incorporated 2018 Financial Report for audited net income, cash flow, margins, balance-sheet liquidity, debt, and year-over-year comparisons.
- Check the actual 2019 financial guidance and subsequent results against management’s outlook.
- Monitor the GSK joint-venture closing, terms, transaction costs and Pfizer’s retained minority interest.
- Track Lyrica’s U.S. loss of exclusivity, other key-product patent litigation and the commercial impact of generic or biosimilar launches.
- Follow FDA remediation and product availability at McPherson and other legacy Hospira facilities.
- Assess the revenue exposure of major products, wholesaler concentration, and changes in pricing, reimbursement and formulary access.